SureTrader SureTrader Nadex Advertisement SureTrader
Home > Boards > US Listed > Medical - Drugs >

RXI Pharmaceuticals Corp (RXII)

RXII RSS Feed
Add RXII Price Alert      Hide Sticky   Hide Intro
Moderator: Inoviorulez
Search This Board: 
Last Post: 2/15/2017 5:23:23 PM - Followers: 141 - Board type: Free - Posts Today: 0

About RXi Pharmaceuticals

RXi Pharmaceuticals Corporation (OTC: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, next-generation RNAi platform.  Therapeutics that use RNA interference, or "RNAi," have great promise because of their ability to "silence," or down-regulate, the expression of a specific gene that may be overexpressed in a disease condition.  Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, RXi's first RNAi product candidate, RXI-109, entered into RXi's first human clinical trial in 2012.  RXI-109 targets connective tissue growth factor (CTGF), a key regulatory of fibrosis and scar formation, and is initially being developed to reduce or inhibit scar formation in the skin following surgery.
 

 



RXi Pharmaceuticals Corp., has received patent approval for their new experimental breast cancer vaccine which became part of the company's arsenal after acquiring Apthera Inc. in April of this year.
The specific patents in question regard using the vaccine NeuVax with the drug Herceptin which is used in women to slow the production of the HER2 protein in tumors, while NeuVax attempts to make the body's immune system fight off cancerous cells.
According to The Telegram:
"The patents also cover using NeuVax in patients not eligible for Herceptin treatment."
With their patent in place the company plans to begin human tests in early 2012.
According to RXi the patents were developed by Dr. George E. Peoples, director of the Cancer Vaccine Development Program for the U.S. Military Cancer Institute and RXi is leasing the patents for their own work.
 

 



This May, RXi Pharmaceuticals Corp. observed two momentous events: The biotechnology company completed its spinoff from Galena Biopharma Inc., and Dr. Geert Cauwenbergh took the helm as president and chief executive officer. The small company's first product, an anti-scarring medication called RXI-109, entered clinical trials this year, and is based on the pioneering work in RNA interference of RXi scientific founder and Nobel Laureate Dr. Craig C. Mello. Dr. Cauwenbergh came to RXi after a long career in pharmaceuticals, most recently as president and chief executive officer of a company he founded, Barrier Therapeutics. What attracted you to come to Worcester? "It was the technology, well, the technology and the chemistry with these people. They're very bright." As a publicly traded company, how do you reconcile the needs of the investors, which are sometimes a short-term desire for profits, with the needs of medical research, which sometimes takes years? "Through business development. Basically what you do as a small biotech is you try to create a big network with people who have interest in various stages of development. ... In two or three years they get antsy and they want to cash in, but at that point in time there will be and there is already a network of business development contacts in place where you can for instance get nondiluted money without having to raise money and go back to the stock market and shareholders by making regional deals or geographic deals ...

NEWS

June 9, 2015 RXi Pharmaceuticals Strengthens Intellectual Property Portfolio for Novel RNAi Platform

http://finance.yahoo.com/news/rxi-pharmaceuticals-strengthens-intellectual-property-110200033.html

Dec 17, 2014 RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301

http://finance.yahoo.com/news/rxi-pharmaceuticals-announces-sustained-effect-120200746.html

Press Releases
RXi Pharmaceuticals to Present at Biotech Showcase™ 2013 - December 19, 2012
RXi Pharmaceuticals Announces Initiation of Second Double-Blind Vehicle Controlled Phase 1 Study With Its Anti-Scarring Compound, RXI-109 - December 5, 2012
RXi Pharmaceuticals Announces Pharmacokinetic Results of its Single Dose Phase 1 Study with RXI-109 in Healthy Volunteers - November 15, 2012
RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2012 - November 14, 2012
RXi Pharmaceuticals to Present at 12th Annual Biotech Symposium - October 16, 2012
RXi Pharmaceuticals Awarded NCI SBIR Funding to Advance Self-Delivering RNAi Technology - October 4, 2012
RXi Pharmaceuticals to Present at 11th Annual BIO Investor Forum - October 2, 2012
RXi Pharmaceuticals Announces Completion of Dosing in Phase 1 Trial for RXI-109 Program - September 24, 2012
RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2012 - August 15, 2012
RXi Pharmaceuticals Appoints Jeannette Graf MD and Leroy Young MD to its Scientific Advisory Board - July 13, 2012
 
Share Statistics
Avg Vol (3 month)3: 215,443
Avg Vol (10 day)3: 145,371
Shares Outstanding5: 338m
Float: 53.34M
% Held by Insiders1: 9.01%
% Held by Institutions1: 0.50%
 



http://www.rxipharma.com/

 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
RXII
Current Price
Volume:
Bid Ask Day's Range
SureTrader
PostSubject
#4341   And I always hated Peanuts. Way over-rated. senderos 02/15/17 05:23:23 PM
#4340   Probably the same presentation. Different audience. realfast95 02/15/17 05:20:26 PM
#4339   And what do you thing the chance is sabaidii2 02/15/17 05:10:44 PM
#4338   conference Wednesday, February 15, 2017 - Thursday, realfast95 02/15/17 04:13:42 PM
#4337   Good point The Other Guy 02/15/17 12:28:38 PM
#4336   Cool tool, thanks. Got it. realfast95 02/15/17 11:31:28 AM
#4335   Well, I guess we learned the O/S from senderos 02/15/17 11:08:40 AM
#4334   http://relationshipscience.com/timothy-j-barberich-p3231671 surf1944 02/15/17 10:59:13 AM
#4333   If I had to guess, we will see The Other Guy 02/15/17 10:44:25 AM
#4331   Is there a relationship between Dr. Frost and Barberich? The Other Guy 02/15/17 10:23:54 AM
#4330   I'm trying to find a relationship between BARBERICH realfast95 02/15/17 10:10:39 AM
#4329   Institutional Investment The Other Guy 02/14/17 02:32:51 PM
#4328   what? Shares short? realfast95 02/14/17 02:13:43 PM
#4327   Hard to say where II stands as of The Other Guy 02/14/17 11:42:11 AM
#4326   Tim Barberich realfast95 02/14/17 11:13:05 AM
#4325   Yeah, odd that individuals would purchase so many shares. InternetForumUser 02/14/17 10:51:02 AM
#4324   two 13G filed realfast95 02/14/17 10:35:43 AM
#4323   I sure hope all this money being spent The Other Guy 02/14/17 09:53:34 AM
#4322   RXi Pharmaceuticals Appoints Medical Oncology Expert, Dr. James realfast95 02/14/17 07:35:05 AM
#4321   Let's see if we have that surge in senderos 02/13/17 12:37:00 PM
#4320   We've already traded more volume than the 90-day senderos 02/13/17 10:05:42 AM
#4319   Im up 4%. thinking i should put a seandy 02/10/17 05:05:56 PM
#4318   Wow. If you are that far down, it senderos 02/10/17 03:07:38 PM
#4317   I won't argue that 13M O/S is relatively The Other Guy 02/10/17 02:47:30 PM
#4316   And 13M is also nothing for an O/S. senderos 02/10/17 01:27:48 PM
#4315   ACInvestorBlog has been pumping endlessly. I finally caught realfast95 02/10/17 10:13:04 AM
#4314   I think it is. Multiple sites have The Other Guy 02/10/17 09:44:16 AM
#4313   Fidelity is showing 6.5M, but maybe that is old. senderos 02/10/17 09:28:48 AM
#4312   The current shares outstanding is ~13M. Still a The Other Guy 02/10/17 09:00:32 AM
#4311   You keep mentioning a reverse split. This senderos 02/10/17 06:34:21 AM
#4310   I have a long position. I have also sabaidii2 02/09/17 09:31:15 PM
#4309   Not quite sure why you dont sell your Marksch1 02/09/17 09:18:01 PM
#4308   JUST MAKE ME SOME *(&%&^ MONEY. IM SICK seandy 02/09/17 07:09:14 PM
#4307   Golly! Geert bought a whole 10,000 shares! Wow! sabaidii2 02/09/17 12:41:09 PM
#4306   10,000 more shares for geert yesterday. Something may Marksch1 02/09/17 12:23:48 PM
#4305   its churning! Drewed 02/09/17 11:30:26 AM
#4304   volume picking back up, its going to be Drewed 02/09/17 11:26:14 AM
#4303   I agree. We could easily hit $1 senderos 02/09/17 10:32:58 AM
#4302   must appreciated input, i am optimistic this stock Drewed 02/09/17 09:33:58 AM
#4301   IMO,most of those sites just want you to senderos 02/09/17 09:31:52 AM
#4300   im not sure im still trying to figure Drewed 02/09/17 09:14:02 AM
#4299   Wow. How in the world do they senderos 02/09/17 09:09:50 AM
#4298   for all the longs here https://www.americanbankingnews.com/2017/02/08/brokerages Drewed 02/09/17 09:01:22 AM
#4297   These pops have happened before only to flame sabaidii2 02/08/17 06:51:18 PM
#4296   I don't know anything for sure, but I senderos 02/08/17 06:28:00 PM
#4295   Until there is fundamental news, all you're seeing sabaidii2 02/08/17 06:19:53 PM
#4294   Nice call. Good volume again. The Other Guy 02/08/17 02:07:45 PM
#4293   And yet, this afternoon, I am predicting the senderos 02/08/17 01:17:21 PM
#4292   By now, RXI has been doing presentations for sabaidii2 02/08/17 01:15:34 PM
#4291   RXi Pharmaceuticals to Present at Leading Investor and senderos 02/08/17 09:28:34 AM
PostSubject